Option chain shows key data for CytoDyn's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for CytoDyn.

CytoDyn (OTC:CYDY) Stock, Option Chain

CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.

Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group’s Most Active List In December

Penny Stocks

Small Cap

Markets

AERG

ATLX

CLNV

CYDY

DTEGY

ETHE

GBTC

GTBIF

HEINY

AMERICAN LITHIUM CORP ORD by American Lithium Corp.

LIACF

NBLD

OTCM

PVCT

REII

RHHBY

WMMVY

ZURVY

On December 14th, the Federal Reserve hiked its key interest rate by 50 basis points. This was the first deceleration in rate hike increases in 2022; between March and November 2022, the interest rate had jumped 25 basis points, 50 basis points and then 75 points four times in a row in between each Federal Reserve meeting.  

Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group&#39;s Most Active List In December

OTC Market Group’s Most Active List In November: A Dive Into The Names Experiencing Volume Changes

AAUKF

ASMIY

BDRBF

CRTD

CWGL

DANOY

EVFM

FISOF

GPOX

JBSAY

Fidelity NASDAQmposite Index Fund ETF-Tracking NASDAQmposite Index

ONEQ

VIHDD

The SPDR S&amp;P 500 ETF Trust (NYSEARCA: SPY) increased by 5.56% in November, recording two subsequent monthly increases for the first time in 2022.

OTC Market Group&#39;s Most Active List In November: A Dive Into The Names Experiencing Volume Changes

Most Active On The OTC Markets In September – A Look Back As October Comes To A Close

ADRNY

AGMRF

AKZOY

BASFY

BLGO

GTII

IMBBY

JSAIY

KNWN

LLKKF

NGLOY

TOMDF

The SPDR S&amp;P 500 ETF Trust (NYSEARCA: SPY) declined by 9.62% in September – its largest decline in 2022.

CytoDyn Inc

Analyst Ratings

Press Releases

CytoDyn Announces Abstract that Highlights Leronlimab's Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques

News

Management

CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development

CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories

Health Care

CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial

CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology

CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories

CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab

CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany

CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer

General

CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors

CytoDyn

Comments

CytoDyn

CytoDyn (CYDY) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell